Results 121 to 130 of about 1,721 (143)

Vericiguat Therapy Is Associated with Reverse Myocardial Remodeling in Chronic Heart Failure with Reduced Ejection Fraction. [PDF]

J Cardiovasc Dev Dis
Bajec T, Žorž N, Ugovšek S, Zemljič G, Cerar A, Frljak S, Okrajšek R, Girandon Sušanj P, Šebeštjen M, Vrtovec B, Poglajen G.   +10 more
europepmc   +1 more source

Association of elevated cyclic GMP levels with hemodynamic changes in HFrEF patients treated with sacubitril/valsartan and vericiguat: a pilot study. [PDF]

Int J Cardiol Heart Vasc
Inoue T, Takahama H, Suzuki H, Arai M, Kikuchi N, Satoh T, Yaoita N, Yamamoto S, Nochioka K, Nakano M, Tatebe S, Takahashi J, Minamino N, Yasuda S.   +13 more
europepmc   +1 more source

Study Design and Baseline Characteristics of the VERINA Study: Phase IV Evidence of Vericiguat for Worsening Heart Failure Management. [PDF]

Cardiol Ther
Abdulakutty J, Abhyankar A, Seth S, Sharma K, Aggarwal RK, Bhalani N, Vijan V, Bansal S, Jain RKP, Banerjee S, Chopra VK, Oomman A, Kahale P, Sodhi P, Gawde A.   +14 more
europepmc   +1 more source

Novel drugs targeting genetic variants: current applications and future prospects in heart failure treatment. [PDF]

Front Mol Biosci
Li X, Bai S, Luo Y.
europepmc   +1 more source

Targeting BCL-2 through Deep Learning-Based Drug Repurposing: A Multimodal Approach Combining Diffusion-Based Generative Modeling, Neural Relational Inference, and In Vitro Validation. [PDF]

J Chem Inf Model
Sayyah E, Tunç H, Çelebi A, Avşar T, Durdağı S.   +4 more
europepmc   +1 more source

The addition of vericiguat to sacubitril/valsartan improved the composite endpoint. Add a finishing touch on heart failure medical therapy by vericiguat as secret ingredient. [PDF]

Eur J Heart Fail
Kinoshita H, Sugino H, Kodama M, Saito M, Sumimoto Y, Masada K, Shimonaga T, Suga A, Toko M, Taniyasu K, Ushirozako S, Katayama Y, Hirahara C, Takada M.   +13 more
europepmc   +1 more source

A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure

International Journal of Molecular Sciences, 2023
Despite recent advances in heart failure (HF) therapy, the risk of cardiovascular (CV) mortality, morbidity, and HF hospitalization (HFH) are major challenges in HF treatment. We aimed to review the potential of vericiguat as a treatment option for HF. A
Ulf Simonsen, Daniela Grimm, Markus Wehland   +2 more
exaly   +2 more sources

Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA) [PDF]

Circulation, 2021
BACKGROUND: In the VICTORIA trial (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction), anemia occurred more often in patients treated with vericiguat (7.6%) than with placebo (5.7%). We explored the association between
Javed Butler, Vojtěch Melenovský, Paul W Armstrong   +2 more
exaly   +4 more sources

Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial [PDF]

European Journal of Heart Failure
AIMS: In the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial, the soluble guanylate cyclase stimulator vericiguat reduced the risk of hospitalization for heart failure (HHF) or cardiovascular death ...
Stefano Corda, Christopher M O'Connor
exaly   +2 more sources

Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction [PDF]

JACC: Heart Failure
Background: In VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction), vericiguat compared with placebo reduced cardiovascular death or heart failure (HF) hospitalization in patients with HF with reduced ejection
Justin Ezekowitz, Lothar Roessig
exaly   +2 more sources